P829: A PHASE III RANDOMIZED CLINICAL TRIAL COMPARING SB12 (PROPOSED ECULIZUMAB BIOSIMILAR) WITH REFERENCE ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
J. H. Jang,
R. Demichelis Gomez,
H. Bumbea,
L. Nogaieva,
L. L. L. Wong,
S. M. Lim,
J. Park,
Y. Kim,
S. Cho
Affiliations
J. H. Jang
1 Hematology-Oncology, Samsung Medical Center, Seoul, South Korea
R. Demichelis Gomez
2 Hematology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
H. Bumbea
3 Hematology, Bucharest Emergency University Hospital, Bucharest, Romania
L. Nogaieva
4 Regional Treatment-Diagnostic Hematology Center, Communal Nonprofit Enterprise Cherkasy Regional Oncology Dispensary of Cherkasy Oblast Council, Cherkasy, Ukraine
L. L. L. Wong
5 Hematology Unit, Hospital Queen Elizabeth, Kota Kinabalu
S. M. Lim
6 Department of Medicine, Hospital Sultanah Aminah, Johor Bahru, Malaysia
J. Park
7 Clinical Development
Y. Kim
8 Biometrics, Samsung Bioepis, Incheon, South Korea
